During the study all injured trauma patients with massive bleeding were successfully treated with HemCon ChitoGauze. Seventy five percent (75%) of all bleeding could be stopped with application of ChitoGauze, while in twenty five percent (25%) of patients ChitoGauze helped to control the severity of bleeding. No side effects were noted in the available follow up of 85.7% of all study subjects. The conclusion of this study is that all degrees (arterial, venous or combination of arterial and venous) of bleeding could be stopped with the HemCon dressing and this offers emergency medical personnel in both civilian and military settings a versatile and highly effective hemostatic solution to help safely stabilize patient for transport to definitive care.

"ChitoGauze has a proven track record of quickly controlling all types of bleeding. HemCon's proprietary chitosan technology provides a cost-effective hemostatic solution to treat routine to most compromised patients, while also providing antibacterial properties that may help reduce the risk of infection. HemCon's ability to stop bleeding at all levels of the continuum of care allows hospitals to add efficiencies to their normal practices as well as greatly reducing everyday expenses, while improving patient outcomes." Said Michael Wax, President and CEO, HemCon "We are very gratified that this important research conducted by Dr. Tan and Dr. Peters has been published and is being presented to the trauma community."

Dr. Tan recently presented the study at the Scientific Program of the European Congress of Trauma and Emergency Surgery (ECTES)/World Trauma Congress in Frankfurt, Germany. Results will also be presented by Dr. Peters at the AIRMED World Congress in Rome, Italy in June. "This international exposure solidifies the recent decision of the U.S.Military Committee on Combat Casualty Care (CoTCCC) to add ChitoGauze to their guidelines for hemorrhage control in tactical field and evacuation care."